Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Security

GH Research PLC Ordinary Shares · GHRS

GHRSNASDAQCommon stockCurrentCIK 1855129Updated Nov 17, 2026

Company: GH Research PLC →

GHRS price & chart

Provider market data

Loading TradingView…

NASDAQ:GHRS on TradingView ↗

TradingView · Data may be delayed

About the company

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression. GH Research PLC’s initial focus is on developing its novel and proprietary mebufotenin therapies for the treatment of patients with TRD.

6-K · 2026-06-04 · 0001140361-26-023952

Company description from the cited filing.

In the news

Seeking Alpha
SEC disclosures

Financials

FY 2025 · USD
Revenue— · FY 2025
Net income-48,258,000USD · FY 2025
Source

20-F · 2026-03-05 · 0001140361-26-007986

2025-01-01 to 2025-12-31

Assets—USD · FY 2025
Cash— · FY 2025
Operating income-60,718,000USD · FY 2025
Source

20-F · 2026-03-05 · 0001140361-26-007986

2025-01-01 to 2025-12-31

Diluted EPS-0.79USD per share · FY 2025
Source

20-F · 2026-03-05 · 0001140361-26-007986

2025-01-01 to 2025-12-31

Some figures are unavailable for this reporting year.

Balance-sheet figures are unavailable pending verification.

cash flow · annual statements
Line itemFY 2025FY 2024FY 2023FY 2022
Cash flows from operating activities:
Profit or LossUSD-48,258,000
Source

20-F · 2026-03-05 · 0001140361-26-007986

2025-01-01 to 2025-12-31

-38,961,000
Source

20-F/A · 2025-07-29 · 0001140361-25-027850

2024-01-01 to 2024-12-31

-35,587,000
Source

20-F · 2024-03-07 · 0001140361-24-011866

2023-01-01 to 2023-12-31

-22,456,000
Source

20-F/A · 2023-06-02 · 0001140361-23-028081

2022-01-01 to 2022-12-31

Additional Financial Items
AdjustmentsForFinanceCostsUSD463,000
Source

20-F · 2026-03-05 · 0001140361-26-007986

2025-01-01 to 2025-12-31

717,000
Source

20-F/A · 2025-07-29 · 0001140361-25-027850

2024-01-01 to 2024-12-31

723,000
Source

20-F · 2024-03-07 · 0001140361-24-011866

2023-01-01 to 2023-12-31

—
AdjustmentsForFinanceIncomeUSD11,128,000
Source

20-F · 2026-03-05 · 0001140361-26-007986

2025-01-01 to 2025-12-31

9,873,000
Source

20-F/A · 2025-07-29 · 0001140361-25-027850

2024-01-01 to 2024-12-31

8,978,000
Source

20-F · 2024-03-07 · 0001140361-24-011866

2023-01-01 to 2023-12-31

—
AdjustmentsForSharebasedPaymentsUSD8,504,000
Source

20-F · 2026-03-05 · 0001140361-26-007986

2025-01-01 to 2025-12-31

1,171,000
Source

20-F/A · 2025-07-29 · 0001140361-25-027850

2024-01-01 to 2024-12-31

2,291,000
Source

20-F · 2024-03-07 · 0001140361-24-011866

2023-01-01 to 2023-12-31

1,671,000
Source

20-F/A · 2023-06-02 · 0001140361-23-028081

2022-01-01 to 2022-12-31

AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD-1,753,000
Source

20-F · 2026-03-05 · 0001140361-26-007986

2025-01-01 to 2025-12-31

-2,129,000
Source

20-F/A · 2025-07-29 · 0001140361-25-027850

2024-01-01 to 2024-12-31

2,621,000
Source

20-F · 2024-03-07 · 0001140361-24-011866

2023-01-01 to 2023-12-31

-7,176,000
Source

20-F/A · 2023-06-02 · 0001140361-23-028081

2022-01-01 to 2022-12-31

GeneralAndAdministrativeExpenseUSD21,953,000
Source

20-F · 2026-03-05 · 0001140361-26-007986

2025-01-01 to 2025-12-31

15,296,000
Source

20-F/A · 2025-07-29 · 0001140361-25-027850

2024-01-01 to 2024-12-31

11,401,000
Source

20-F · 2024-03-07 · 0001140361-24-011866

2023-01-01 to 2023-12-31

10,070,000
Source

20-F/A · 2023-06-02 · 0001140361-23-028081

2022-01-01 to 2022-12-31

IncreaseDecreaseInWorkingCapitalUSD3,094,000
Source

20-F · 2026-03-05 · 0001140361-26-007986

2025-01-01 to 2025-12-31

-188,000
Source

20-F/A · 2025-07-29 · 0001140361-25-027850

2024-01-01 to 2024-12-31

-1,645,000
Source

20-F · 2024-03-07 · 0001140361-24-011866

2023-01-01 to 2023-12-31

-2,159,000
Source

20-F/A · 2023-06-02 · 0001140361-23-028081

2022-01-01 to 2022-12-31

InterestPaidClassifiedAsOperatingActivitiesUSD639,000
Source

20-F · 2026-03-05 · 0001140361-26-007986

2025-01-01 to 2025-12-31

723,000
Source

20-F/A · 2025-07-29 · 0001140361-25-027850

2024-01-01 to 2024-12-31

648,000
Source

20-F · 2024-03-07 · 0001140361-24-011866

2023-01-01 to 2023-12-31

22,000
Source

20-F/A · 2023-06-02 · 0001140361-23-028081

2022-01-01 to 2022-12-31

InterestReceivedClassifiedAsOperatingActivitiesUSD12,060,000
Source

20-F · 2026-03-05 · 0001140361-26-007986

2025-01-01 to 2025-12-31

7,076,000
Source

20-F/A · 2025-07-29 · 0001140361-25-027850

2024-01-01 to 2024-12-31

4,283,000
Source

20-F · 2024-03-07 · 0001140361-24-011866

2023-01-01 to 2023-12-31

500,000
Source

20-F/A · 2023-06-02 · 0001140361-23-028081

2022-01-01 to 2022-12-31

PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD197,000
Source

20-F · 2026-03-05 · 0001140361-26-007986

2025-01-01 to 2025-12-31

304,000
Source

20-F/A · 2025-07-29 · 0001140361-25-027850

2024-01-01 to 2024-12-31

219,000
Source

20-F · 2024-03-07 · 0001140361-24-011866

2023-01-01 to 2023-12-31

—
ProceedsFromIssuingSharesUSD0
Source

20-F · 2026-03-05 · 0001140361-26-007986

2025-01-01 to 2025-12-31

0
Source

20-F/A · 2025-07-29 · 0001140361-25-027850

2024-01-01 to 2024-12-31

15,000
Source

20-F · 2024-03-07 · 0001140361-24-011866

2023-01-01 to 2023-12-31

0
Source

20-F/A · 2023-06-02 · 0001140361-23-028081

2022-01-01 to 2022-12-31

Lines labelled “Derived” are calculated from reported figures.

income statement · annual statements
Line itemFY 2025FY 2024FY 2023FY 2022
Selling, General and Administrative ExpenseUSD21,953,000
Source

20-F · 2026-03-05 · 0001140361-26-007986

2025-01-01 to 2025-12-31

15,296,000
Source

20-F/A · 2025-07-29 · 0001140361-25-027850

2024-01-01 to 2024-12-31

11,401,000
Source

20-F · 2024-03-07 · 0001140361-24-011866

2023-01-01 to 2023-12-31

10,070,000
Source

20-F/A · 2023-06-02 · 0001140361-23-028081

2022-01-01 to 2022-12-31

Additional Financial Items
ApplicableTaxRatenumber0.13
Source

20-F · 2026-03-05 · 0001140361-26-007986

2025-01-01 to 2025-12-31

0.13
Source

20-F/A · 2025-07-29 · 0001140361-25-027850

2024-01-01 to 2024-12-31

0.13
Source

20-F · 2024-03-07 · 0001140361-24-011866

2023-01-01 to 2023-12-31

0.13
Source

20-F/A · 2023-06-02 · 0001140361-23-028081

2022-01-01 to 2022-12-31

BasicEarningsLossPerShareUSD per share-0.79
Source

20-F · 2026-03-05 · 0001140361-26-007986

2025-01-01 to 2025-12-31

-0.75
Source

20-F/A · 2025-07-29 · 0001140361-25-027850

2024-01-01 to 2024-12-31

-0.68
Source

20-F · 2024-03-07 · 0001140361-24-011866

2023-01-01 to 2023-12-31

-0.43
Source

20-F/A · 2023-06-02 · 0001140361-23-028081

2022-01-01 to 2022-12-31

DilutedEarningsLossPerShareUSD per share-0.79
Source

20-F · 2026-03-05 · 0001140361-26-007986

2025-01-01 to 2025-12-31

-0.75
Source

20-F/A · 2025-07-29 · 0001140361-25-027850

2024-01-01 to 2024-12-31

-0.68
Source

20-F · 2024-03-07 · 0001140361-24-011866

2023-01-01 to 2023-12-31

-0.43
Source

20-F/A · 2023-06-02 · 0001140361-23-028081

2022-01-01 to 2022-12-31

EmployeeBenefitsExpenseUSD21,282,000
Source

20-F · 2026-03-05 · 0001140361-26-007986

2025-01-01 to 2025-12-31

12,036,000
Source

20-F/A · 2025-07-29 · 0001140361-25-027850

2024-01-01 to 2024-12-31

10,200,000
Source

20-F · 2024-03-07 · 0001140361-24-011866

2023-01-01 to 2023-12-31

6,390,000
Source

20-F/A · 2023-06-02 · 0001140361-23-028081

2022-01-01 to 2022-12-31

ExpenseFromSharebasedPaymentTransactionsWithEmployeesUSD8,504,000
Source

20-F · 2026-03-05 · 0001140361-26-007986

2025-01-01 to 2025-12-31

1,171,000
Source

20-F/A · 2025-07-29 · 0001140361-25-027850

2024-01-01 to 2024-12-31

2,291,000
Source

20-F · 2024-03-07 · 0001140361-24-011866

2023-01-01 to 2023-12-31

1,671,000
Source

20-F/A · 2023-06-02 · 0001140361-23-028081

2022-01-01 to 2022-12-31

FinanceCostsUSD463,000
Source

20-F · 2026-03-05 · 0001140361-26-007986

2025-01-01 to 2025-12-31

717,000
Source

20-F/A · 2025-07-29 · 0001140361-25-027850

2024-01-01 to 2024-12-31

723,000
Source

20-F · 2024-03-07 · 0001140361-24-011866

2023-01-01 to 2023-12-31

244,000
Source

20-F/A · 2023-06-02 · 0001140361-23-028081

2022-01-01 to 2022-12-31

FinanceIncomeUSD11,128,000
Source

20-F · 2026-03-05 · 0001140361-26-007986

2025-01-01 to 2025-12-31

9,873,000
Source

20-F/A · 2025-07-29 · 0001140361-25-027850

2024-01-01 to 2024-12-31

8,978,000
Source

20-F · 2024-03-07 · 0001140361-24-011866

2023-01-01 to 2023-12-31

1,166,000
Source

20-F/A · 2023-06-02 · 0001140361-23-028081

2022-01-01 to 2022-12-31

GeneralAndAdministrativeExpenseUSD21,953,000
Source

20-F · 2026-03-05 · 0001140361-26-007986

2025-01-01 to 2025-12-31

15,296,000
Source

20-F/A · 2025-07-29 · 0001140361-25-027850

2024-01-01 to 2024-12-31

11,401,000
Source

20-F · 2024-03-07 · 0001140361-24-011866

2023-01-01 to 2023-12-31

10,070,000
Source

20-F/A · 2023-06-02 · 0001140361-23-028081

2022-01-01 to 2022-12-31

IncomeTaxExpenseContinuingOperationsUSD0
Source

20-F · 2026-03-05 · 0001140361-26-007986

2025-01-01 to 2025-12-31

0
Source

20-F/A · 2025-07-29 · 0001140361-25-027850

2024-01-01 to 2024-12-31

0
Source

20-F · 2024-03-07 · 0001140361-24-011866

2023-01-01 to 2023-12-31

0
Source

20-F/A · 2023-06-02 · 0001140361-23-028081

2022-01-01 to 2022-12-31

InterestExpenseUSD——63,000
Source

20-F · 2024-03-07 · 0001140361-24-011866

2023-01-01 to 2023-12-31

0
Source

20-F/A · 2023-06-02 · 0001140361-23-028081

2022-01-01 to 2022-12-31

InterestExpenseOnLeaseLiabilitiesUSD35,000
Source

20-F · 2026-03-05 · 0001140361-26-007986

2025-01-01 to 2025-12-31

48,000
Source

20-F/A · 2025-07-29 · 0001140361-25-027850

2024-01-01 to 2024-12-31

100,000
Source

20-F · 2024-03-07 · 0001140361-24-011866

2023-01-01 to 2023-12-31

—
PostemploymentBenefitExpenseDefinedContributionPlansUSD600,000
Source

20-F · 2026-03-05 · 0001140361-26-007986

2025-01-01 to 2025-12-31

300,000
Source

20-F/A · 2025-07-29 · 0001140361-25-027850

2024-01-01 to 2024-12-31

100,000
Source

20-F · 2024-03-07 · 0001140361-24-011866

2023-01-01 to 2023-12-31

—
ProfitLossAttributableToOwnersOfParentUSD-48,258,000
Source

20-F · 2026-03-05 · 0001140361-26-007986

2025-01-01 to 2025-12-31

-38,961,000
Source

20-F/A · 2025-07-29 · 0001140361-25-027850

2024-01-01 to 2024-12-31

-35,587,000
Source

20-F · 2024-03-07 · 0001140361-24-011866

2023-01-01 to 2023-12-31

-22,456,000
Source

20-F/A · 2023-06-02 · 0001140361-23-028081

2022-01-01 to 2022-12-31

ProfitLossBeforeTaxUSD-48,258,000
Source

20-F · 2026-03-05 · 0001140361-26-007986

2025-01-01 to 2025-12-31

-38,961,000
Source

20-F/A · 2025-07-29 · 0001140361-25-027850

2024-01-01 to 2024-12-31

-35,587,000
Source

20-F · 2024-03-07 · 0001140361-24-011866

2023-01-01 to 2023-12-31

-22,456,000
Source

20-F/A · 2023-06-02 · 0001140361-23-028081

2022-01-01 to 2022-12-31

ProfitLossFromOperatingActivitiesUSD-60,718,000
Source

20-F · 2026-03-05 · 0001140361-26-007986

2025-01-01 to 2025-12-31

-50,312,000
Source

20-F/A · 2025-07-29 · 0001140361-25-027850

2024-01-01 to 2024-12-31

-41,222,000
Source

20-F · 2024-03-07 · 0001140361-24-011866

2023-01-01 to 2023-12-31

-30,554,000
Source

20-F/A · 2023-06-02 · 0001140361-23-028081

2022-01-01 to 2022-12-31

ResearchAndDevelopmentExpenseUSD38,765,000
Source

20-F · 2026-03-05 · 0001140361-26-007986

2025-01-01 to 2025-12-31

35,016,000
Source

20-F/A · 2025-07-29 · 0001140361-25-027850

2024-01-01 to 2024-12-31

29,821,000
Source

20-F · 2024-03-07 · 0001140361-24-011866

2023-01-01 to 2023-12-31

20,484,000
Source

20-F/A · 2023-06-02 · 0001140361-23-028081

2022-01-01 to 2022-12-31

Lines labelled “Derived” are calculated from reported figures.

Offerings

Registration 333-295872

F-3 · 2026-05-14 · 0001140361-26-021176

Terms from the governing filing for this registration; not a claim that the offering is open today.

Filing attachments

ef20080548_ex99-1.htm · 6-K · 2026-11-13

Exhibit 99.1 GH RESEARCH PLC Unaudited condensed consolidated interim statement of comprehensive loss Three months ended Nine months ended September 30, September 30, September 30, …

6-K · 2026-11-13 · 0001140361-26-043544

Read attachment ↗
ef20080548_ex99-2.htm · 6-K · 2026-11-13

Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. You should read this discussion and analysis in conjunction with our unaudited condensed consolidated interim financial statements, including the notes thereto, as of and for the three and nine months ended September 30, 2026. You should also read…

6-K · 2026-11-13 · 0001140361-26-043544

Read attachment ↗
ef20075260_ex99-1.htm · 6-K · 2026-08-06

Exhibit 99.1 GH RESEARCH PLC Unaudited condensed consolidated interim statement of comprehensive loss Three months ended Six months ended June 30, June 30, June 30, …

6-K · 2026-08-06 · 0001140361-26-031506

Read attachment ↗
ef20075260_ex99-2.htm · 6-K · 2026-08-06

Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. You should read this discussion and analysis in conjunction with our unaudited condensed consolidated interim financial statements, including the notes thereto, as of and for the three and six months ended June 30, 2026. You should also read this …

6-K · 2026-08-06 · 0001140361-26-031506

Read attachment ↗
ef20075541_ex99-1.htm · 6-K · 2026-06-04

Exhibit 99.1 GH Research Announces Publication of Phase 2a Postpartum Depression Results Dublin, Ireland, June 4, 2026 - GH Research PLC (Nasdaq: GHRS) today announced the publication of the full results from its Phase 2a trial in postpartum depression (PPD) and the acceptance of two oral presentations at the 37th World Congress of Neuropsychopharmacology (CINP 2026). The peer-reviewed article, titled “Inhaled Mebufotenin (GH001) for Adult Patients with Postpartum Depression: A Phase 2a Open-…

6-K · 2026-06-04 · 0001140361-26-023952

Read attachment ↗
ef20074384_ex99-1.htm · 6-K · 2026-05-21

Exhibit 99.1 Apparent sadness Reported sadness Concentration difficulty Lassitude Inability to feel Mean (SD) Change from Baseline in MADRS Anhedonia Factor Items at Day 8 Results Disposition and Baseline Characteristics Disposition and baseline characteristics are presented in Table 1 Mean (SD) total MADRS scores at baseline were 29.0 (5.4) for GH001 and 28.2 (4.6) for placebo. Baseline MADRS anhedonia factor scores were 17.6 (3.2) for GH001 and 17.4 (2.6) for placebo Table 1. Patient Disposit…

6-K · 2026-05-21 · 0001140361-26-022330

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.